James T. Willerson

Research.com Recognitions

• 2006 - Libin/AHFMR Prize in Cardiovascular Research
• 2003 - Distinguished Scientist Award, American Heart Association
• 2000 - Distinguished Fellowship Award, American College of Cardiology (ACC)
• 1997 - Member of the National Academy of Medicine (NAM)
• 1992 - Fellow of the American Association for the Advancement of Science (AAAS)
• Member of the Association of American Physicians
• Member of the Association of American Physicians

Overview

Best Publications

• Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein

  Paul M. Ridker;Eleanor Danielson;Francisco A. H. Fonseca;Jacques Genest

  5968
  Citations

• From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II.

  Morteza Naghavi;Peter Libby;Erling Falk;S. Ward Casscells;S. Ward Casscells

  4689
  Citations

• Direct Proinflammatory Effect of C-Reactive Protein on Human Endothelial Cells

  Vincenzo Pasceri;Vincenzo Pasceri;James T. Willerson;James T. Willerson;Edward T. H. Yeh

  3307
  Citations

• Circadian variation in the frequency of onset of acute myocardial infarction

  J. E. Muller;P. H. Stone;Z. G. Turi;J. D. Rutherford

  2403
  Citations

• Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-α, in Patients With Moderate-to-Severe Heart Failure Results of the Anti-TNF Therapy Against Congestive Heart failure (ATTACH) Trial

  Eugene S. Chung;Milton Packer;Kim Hung Lo;Adedigbo A. Fasanmade

  2186
  Citations

• Inflammation as a cardiovascular risk factor.

  James T. Willerson;Paul M. Ridker

  1657
  Citations

• Appointment of New Associate Editor for Circulation

  James T. Willerson

  1546
  Citations

• Modulation of C-Reactive Protein–Mediated Monocyte Chemoattractant Protein-1 Induction in Human Endothelial Cells by Anti-Atherosclerosis Drugs

  Vincenzo Pasceri;Vincenzo Pasceri;Jed Chang;James T. Willerson;James T. Willerson;Edward T. H. Yeh

  1410
  Citations

• The VIVA Trial Vascular Endothelial Growth Factor in Ischemia for Vascular Angiogenesis

  Timothy D. Henry;Brian H. Annex;George R. McKendall;Michael A. Azrin

  1354
  Citations

• Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.

  Paul M Ridker;Eleanor Danielson;Francisco Ah Fonseca;Jacques Genest

  1300
  Citations

• Thrombolysis inMyocardial Infarction (TIMI) Trial, Phase I:acomparison between intravenous tissue plasminogen activator andintravenous streptokinase*

  J. H. Chesebro;G. Knatterud;R. Roberts;J. Borer

  1182
  Citations

• Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial.

  EJ Topol;AM Lincoff;RM Califf;EM Ohman

  949
  Citations

• A Randomized Trial of Rosuvastatin in the Prevention of Venous Thromboembolism

  Robert J. Glynn;Eleanor Danielson;Francisco A.H. Fonseca;Jacques Genest

  914
  Citations

• Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease.

  P. D. Hirsh;L. D. Hillis;W. B. Campbell;B. G. Firth

  833
  Citations

• Leukocyte count and coronary heart disease: Implications for risk assessment

  Mohammad Madjid;Mohammad Madjid;Imran Awan;Imran Awan;James T. Willerson;James T. Willerson;S. Ward Casscells;S. Ward Casscells;S. Ward Casscells

  827
  Citations

• Risk factors for sudden death after acute myocardial infarction: Two-year follow-up☆

  Jhulan Mukharji;Robert E Rude;W.Kenneth Poole;Nancy Gustafson

  757
  Citations

• Modulation of Vascular Inflammation In Vitro and In Vivo by Peroxisome Proliferator–Activated Receptor-γ Activators

  Vincenzo Pasceri;Henry D. Wu;James T. Willerson;James T. Willerson;Edward T. H. Yeh

  742
  Citations

• The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: Contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis☆

  Peter H. Stone;Peter H. Stone;James E. Muller;James E. Muller;Tyler Hartwell;Tyler Hartwell;B. J. York;B. J. York

  730
  Citations

• Suppression of canonical Wnt/β-catenin signaling by nuclear plakoglobin recapitulates phenotype of arrhythmogenic right ventricular cardiomyopathy

  Eduardo Garcia-Gras;Raffaella Lombardi;Michael J. Giocondo;James T. Willerson

  678
  Citations

• The Pathology of Vulnerable Plaque

  Renu Virmani;Allen P Burke;James T Willerson;Andrew Farb

  18
  Citations